Quick Search


 

Result Summaries: lamivudine

ViiV
Study ID
   Phase    Title Summary (Download)
101822 phase 3 A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study) (1 citation(s)) Click here to download result summary.
105816 Phase 4 A post-marketing surveillance to monitor the safety of 3TCTM (Lamivudine 150mg) administered in Korean subjects according to the prescribing information (0 citation(s)) Click here to download result summary.
111945_1 N/A Studies using DAD - HIV and Hepatitis Coinfection Initiative (5 citation(s)) Click here to download result summary.
111950_1 n\a Fractures over time stratified by HIV infection and Antiretroviral Therapy (ART) exposure (0 citation(s)) Click here to download result summary.
112295 N/A Drug Use Investigation for Epivir tablet (HRD Cooperative Investigation) (0 citation(s)) Click here to download result summary.
112298 Phase 2 Special Drug Use Investigation for Epivir tablet (Pregnancy) (HRD Cooperative Investigation) (0 citation(s)) Click here to download result summary.
112330 phase 2 Drug Use Investigation for Epzicom tablet (HRD Cooperative Investigation) (0 citation(s)) Click here to download result summary.
112348 phase 4 Special Drug Use Investigation for EPZICOM® (abacavir sulfate/lamivudine) tablet (Pregnancy) (HRD Cooperative Investigation) (0 citation(s)) Click here to download result summary.
112872_1 n\a HIV treatment and CVD events - Ingenix. Retrospective Database Analysis of Patients with Human Immunodeficiency Virus (HIV) Treatment and Cardiovascular Disease (CVD) Events (0 citation(s)) Click here to download result summary.
112874_1 N/A Incidence and Risk Factors for New-onset Diabetes in HIV-infected Patients. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study (1 citation(s)) Click here to download result summary.
112877_3 N/A Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration (5 citation(s)) Click here to download result summary.
112878_2 N/A Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus (2 citation(s)) Click here to download result summary.
112884_1 N/A The metabolic syndrome in the DAD Study (2 citation(s)) Click here to download result summary.
112885_1 N/A Antiretroviral Pregnancy Registry (APR)-Risk of birth defects associated with exposure to GSK HIV drugs during pregnancy (1 citation(s)) Click here to download result summary.
112886_2 N/A Changes over time in risk factors for cardiovascular disease and use of Lipid-Lowering drugs in HIV-infected individuals and impact on myocardial infarction. (0 citation(s)) Click here to download result summary.
112887_1 N/A Studies using DAD - Effects of different interventions to improve ART-associated dyslipidemia (1 citation(s)) Click here to download result summary.
112889_2 N/A HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies (0 citation(s)) Click here to download result summary.
113039_1 N/A Studies using DAD - Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? (1 citation(s)) Click here to download result summary.
113154_1 N/A Predictors of hypertension and changes of blood pressure in HIV-infected patients (2 citation(s)) Click here to download result summary.
113156_1 N/A Studies using the VA - Studies done under the Oversight Committee for the Evaluation of the metabolic complications of HAART (2 citation(s)) Click here to download result summary.
113329_1 n\a Lactic acid levels in children pre- and perinatally treated with antiretrovirals to prevent HIV transmission (Giaquinto; Hyperlactatemia in infants with in utero exposure to ZDV/3TC ) (2 citation(s)) Click here to download result summary.
115325 phase 1 A Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™ Administered Concurrently in Healthy Adult Subjects (0 citation(s)) Click here to download result summary.
204857 phase 4 An Open-label Single-Center, 4-Period William’s Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects (0 citation(s)) Click here to download result summary.
C93-015 Phase 1 A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) in Patients with Impaired Hepatic Function (0 citation(s)) Click here to download result summary.
COLA4005 Phase 2 A Phase II, Open-Label, Randomized Study of the Efficacy and Safety of EPIVIR 150mg Twice-Daily Versus EPIVIR 300mg Once-Daily When Administered for 24 Weeks in Combination with FDA-Approved Dosage Regimens of ZERIT and Either CRIXIVAN or VIRACEPT in Subjects with HIV-1 Infection (1 citation(s)) Click here to download result summary.
EPV10001 Phase 1 An Open-Label, Randomized, 2-way Cross-over Study to Compare the Steady-State Pharmacokinetics of Lamivudine and Lamivudine Triphosphate Following Lamivudine 300mg Once Daily Versus EPIVIR 150mg Twice a Day in Healthy Volunteers (2 citation(s)) Click here to download result summary.
EPV20001 Phase 3 A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg QD vs Lamivudine 150mg BID in Combination with Zidovudine 300mg BID and Efavirenz 600mg QD in Antiretroviral-Naïve Adults with HIV-1 Infection. 48-Week Report (2 citation(s)) Click here to download result summary.
EPV40001 Phase 4 Open-Label, Pilot Study To Explore The Early Antiviral Activity And Tolerability Of Abacavir And Epivir When Each Is Administered Once-Daily Within A Triple Combination Regimen Including Abacavir, Epivir And Retrovir Compared to The Triple Combination Regimen Administered Twice-Daily In Antiretr ... (3 citation(s)) Click here to download result summary.
EPZ108859 phase 3 Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects followed by an Optional 60-Week Treatment Extension Phase (10 citation(s)) Click here to download result summary.
NUCA1004 Phase 1 A Single-Dose Study of GR109714X (3TCTM) in HIV-Infected Patients with Impaired Renal Function (1 citation(s)) Click here to download result summary.
NUCA1006 Phase 1 Bioequivalence of Lamivudine [GR109714X, 3TCTM] 75mg, 100mg, and 300mg Tablets in Asymptomatic HIV-Infected Male Patients (0 citation(s)) Click here to download result summary.
NUCA2002 Phase 2 A Phase I/II Study of 3TC (GR109714X) in Children With HIV Infection (6 citation(s)) Click here to download result summary.
NUCA2005 Phase 2 A phase I/II study to evaluate the safety, toxicity and preliminary efficacy of combinations of lamivudine (3TC), Zidovudine (ZDV) and Didanosine (ddI) in children with HIV infection. (0 citation(s)) Click here to download result summary.
NUCA3001 Phase 3 A Randomized, Double-Blind, Multi-center Trial to Compare the Safety and Efficacy of 3TCTM Monotherapy Versus Zidovudine (ZDV) Monotherapy Versus 3TCTM Administered Concurrently with ZDV in the Treatment of HIV-1 Infected Patients who are ZDV-Naïve (?4 weeks) with CD4 Cell Counts of 200-500 cell ... (7 citation(s)) Click here to download result summary.
NUCA3002 Phase 3 A Randomized 3TCTM, ddC Double-Blind (ZDV Open-labeled) Multi-center Trial to Evaluate the Safety and Efficacy of 3TCTM (low dose) Administered Concurrently with Zidovudine (ZDV) versus 3TCTM (high dose) Administered Concurrently with ZDV Versus Dideoxycytidine (ddC) Administered… (1 citation(s)) Click here to download result summary.
NUCB1002 Phase 1 A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) in Patients With Impaired Hepatic Function (Protocol No: C93-015) (0 citation(s)) Click here to download result summary.
NUCB1003 Phase 1 A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) Following Oral Dosing in Subjects With Impaired Renal Function (0 citation(s)) Click here to download result summary.
NUCB1004 Phase 1 A study to investigate the comparative bioavailability of two oral formulations of GR109714X (Lamivudine). (0 citation(s)) Click here to download result summary.
NUCB1007 Phase 1 A Study to Investigate the Pharmacokinetic Interaction Between Lamivudine and Alpha-Interferon in Healthy Subjects (0 citation(s)) Click here to download result summary.
NUCB2001 Phase 2 A phase I/II study of the safety, pharmacokinetics and preliminary activity of 3TC (GR109714X) in HIV-positive, asymptomatic and mild ARC patients. (0 citation(s)) Click here to download result summary.
NUCB3001 Phase 3 A Randomized, Controlled 3TCTM Double-Blinded Trial to Compare the Safety and Efficacy of 3TCTM in Combination with Zidovudine (ZDV) Versus Zidovudine Monotherapy in Treating HIV-1 Infected Patients Who Are Zidovudine Therapy-Naïve With a CD4 Cell Count Between 100 - 400 cells/mm3. (11 citation(s)) Click here to download result summary.
NUCB3002 Phase 3 A Randomized, Controlled, Lamivudine (3TCTM) Double-Blinded Trial to Compare the Safety and Efficacy of Zidovudine (ZDV) Monotherapy Versus Lamivudine Plus ZDV in Combination in Treating HIV-1 Infected Patients who are Zidovudine Therapy-Experienced With a CD4+ Cell Count Between 100cells/mm3 to ... (11 citation(s)) Click here to download result summary.
NUCB3007 Phase 3 A Randomized, Controlled, Double-Blinded, Clinical End-Point Trial to Compare the Efficacy and Safety of 3TC Versus 3TC + Loviride Versus Placebo in the Treatment of HIV-1 Infected Persons Taking Concurrent Zidovudine-Containing Treatment Regimens With CD4 Counts Between 25cells/mm3 to 250cells/mm3 (23 citation(s)) Click here to download result summary.
NUCB3009 Phase 3 A Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Two Dosage Regimens of Lamivudine in Patients with Chronic Hepatitis B Infection (1 citation(s)) Click here to download result summary.
NUCB3010 Phase 3 A Study of Lamivudine and Alpha-Interferon in Patients with Chronic Hepatitis B Infection Who are Interferon Treatment Naive (1 citation(s)) Click here to download result summary.
NUCB3014 Phase 3 A Study of Lamivudine in Patients With HBeAb Positive Chronic Hepatitis B Infection; Week 52 (End of Treatment) Analysis (1 citation(s)) Click here to download result summary.
NUCB3017 Phase 3 A Study of Extended Lamivudine Treatment for Hepatitis B Subjects Previously Enrolled in Phase II or Phase III Lamivudine Trials. (0 citation(s)) Click here to download result summary.
NUCB3018 Phase 3 A Follow-On Study to Determine the Safety and Efficacy of Long-Term Lamivudine Treatment in Patients with Chronic Hepatitis B Infection (5 Year Treatment Plus 6 Months Off-treatment Follow-Up) (4 citation(s)) Click here to download result summary.
NUCB3026 Phase 3 A Double-Blind, Placebo-Controlled Study Of Lamivudine In Subjects In China With Chronic Hepatitis B Infection Followed By Long-Term (5 Years) Lamivudine Treatment (0 citation(s)) Click here to download result summary.
NUCB4006 Phase 4 A Double-blind Placebo Controlled Clinical End-points Trial of Lamivudine in Patients with Hepatitis B Related Cirrhosis (1 citation(s)) Click here to download result summary.
ZEFT02 Phase 3 Open-label study of lamivudine in combination with interferon in treating chronic hepatitis B, anti HBe positive patients who are interferon-therapy naïve. (0 citation(s)) Click here to download result summary.
ZEFT03 Phase 3 Open label treatment with lamivudine in patients with chronic hepatitis B, Anti HBe (Hepatitis B envelope) Positive, who have not responded to previous treatment with interferon. Study of lamivudine added to the interferon treatment in comparison to the sequential treatment (0 citation(s)) Click here to download result summary.